AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis

2026-03-28 - 15:10

https://mms.businesswire.com/media/20260328320362/en/2759690/19/Lawrence_Eichenfield_Christophe_Piketty_16-9.mp4 Read More